SOMERSET, N.J., June 29, 2026
Terumo Interventional Systems (TIS), a division of Terumo Corporation, has announced the successful completion of the first U.S. clinical procedure using the OPUSWAVE® Dual Sensor Imaging System, marking a significant milestone in the advancement of coronary intravascular imaging technology. The landmark procedure was performed on June 15 by Annapoorna S. Kini, MD, MRCP, FACC, at Mount Sinai Fuster Heart Hospital in New York, introducing physicians in the United States to a next-generation imaging platform that combines Optical Frequency Domain Imaging (OFDI) and Intravascular Ultrasound (IVUS) into a single catheter. By integrating these two complementary imaging modalities, the OPUSWAVE System enables clinicians to simultaneously visualize deep vessel structures alongside high-resolution surface details, providing a more comprehensive assessment of coronary anatomy during complex cardiovascular interventions. This innovative technology represents an important advancement in precision-guided cardiovascular care, helping physicians make more informed treatment decisions while improving confidence during challenging interventional procedures.
Dual Sensor Technology Enhances Coronary Imaging Precision
The OPUSWAVE® Dual Sensor Imaging System addresses one of the most significant challenges in interventional cardiology by eliminating the need to choose between deep tissue visualization offered by IVUS and the exceptional surface resolution provided by OFDI. Through its proprietary DualView® Imaging Catheter, physicians can simultaneously evaluate plaque composition, lesion morphology, vessel architecture, and stent deployment using a single imaging platform. This dual-imaging capability provides a more complete understanding of coronary disease while supporting accurate procedural planning and optimization.
The system has been engineered with a compact 2.6 French catheter profile, compatibility with 6 French guide catheters, advanced hydrophilic coating, and an extended 150 mm pullback for both imaging technologies, allowing physicians to perform longer imaging runs without compromising procedural workflow. In addition, clinicians can select between IVUS-only, OFDI-only, or simultaneous dual-imaging modes, enabling flexible imaging strategies tailored to the specific clinical requirements of each patient while maintaining procedural efficiency.
Innovation Supports Better Clinical Decision-Making
Advertisement
The successful first U.S. procedure reflects Terumo’s continued commitment to advancing minimally invasive cardiovascular technologies that improve diagnostic accuracy and therapeutic outcomes. Physicians involved in the initial clinical use highlighted that access to both imaging modalities simultaneously offers a more complete visualization of coronary anatomy, allowing greater confidence when managing complex lesions and optimizing stent placement. According to company leadership, market research has consistently demonstrated that clinicians value technologies capable of providing clearer vessel visualization, improved diagnostic confidence, and enhanced procedural decision-making, all of which are central to the OPUSWAVE platform. The imaging system’s ability to combine complementary technologies into a single catheter also streamlines workflow by reducing the need to exchange devices during procedures.
Terumo believes the OPUSWAVE Imaging System represents the next evolution of intravascular imaging, supporting precision medicine through comprehensive real-time visualization of coronary pathology. As cardiovascular disease remains one of the world’s leading causes of mortality, advanced imaging technologies such as the OPUSWAVE System are expected to play an increasingly important role in guiding complex coronary interventions, improving procedural efficiency, and supporting personalized patient care. The successful introduction of OPUSWAVE in the United States reinforces Terumo’s leadership in cardiovascular medical technology while expanding physician access to innovative imaging solutions that may improve clinical outcomes for patients undergoing coronary interventions across modern catheterization laboratories.
Source: Terumo press release
